Skip to content
2000
Volume 24, Issue 5
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873

Abstract

Due to insulin resistance and excessive blood sugar levels, type 1 diabetes mellitus (T1DM) is characterized by pancreatic cell loss. This condition affects young people at a higher rate than any other chronic autoimmune disease. Regardless of the method, exogenous insulin cannot substitute for insulin produced by a healthy pancreas. An emerging area of medicine is pancreatic and islet transplantation for type 1 diabetics to restore normal blood sugar regulation. However, there are still obstacles standing in the way of the widespread use of these therapies, including very low availability of pancreatic and islets supplied from human organ donors, challenging transplantation conditions, high expenses, and a lack of easily accessible methods. Efforts to improve Type 1 Diabetes treatment have been conducted in response to the disease's increasing prevalence. Type 1 diabetes may one day be treated with stem cell treatment. Stem cell therapy has proven to be an effective treatment for type 1 diabetes. Recent progress in stem cell-based diabetes treatment is summarised, and the authors show how to isolate insulin-producing cells (IPCs) from a variety of progenitor cells.

Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303256582230919093535
2024-04-01
2025-01-18
Loading full text...

Full text loading...

/content/journals/emiddt/10.2174/0118715303256582230919093535
Loading

  • Article Type:
    Review Article
Keyword(s): autoimmune disease; Diabetes; insulin; mesenchymal stem cell; pancreatic cell; stem cells
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test